Spero sought approval of tebipenem on the strength of a phase 3 trial – ADAPT-PO – which showed that the drug was equivalent to standard care with intravenous ertapenem in patients with cUTI ...

When seen with granular casts, renal tubule epithelial cells are highly predictive of acute tubular necrosis and can help to exclude prerenal acute kidney injury, seen in postoperative patients ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Acute and chronic conditions typically differ in how they develop and how long they last. Broadly speaking, acute conditions occur suddenly, have immediate or rapidly developing symptoms, and are ...

Mission Statement: Evidence-based Complementary and Alternative Medicine (eCAM) is an international, peer-reviewed journal that seeks to understand the sources and to encourage rigorous research ...